These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 25617843)

  • 21. Loss of high-affinity prostacyclin receptors in platelets and the lack of prostaglandin-induced inhibition of platelet-stimulated thrombin generation in subjects with spinal cord injury.
    Kahn NN; Bauman WA; Sinha AK
    Proc Natl Acad Sci U S A; 1996 Jan; 93(1):245-9. PubMed ID: 8552614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Organic nitrates and compounds that increase intraplatelet cyclic guanosine monophosphate (cGMP) levels enhance the antiaggregating effects of the stable prostacyclin analogue iloprost.
    Anfossi G; Massucco P; Mularoni E; Cavalot F; Mattiello L; Trovati M
    Prostaglandins Leukot Essent Fatty Acids; 1993 Nov; 49(5):839-45. PubMed ID: 7508131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impaired platelet prostacyclin receptor activity: a monozygotic twin study discordant for spinal cord injury.
    Kahn N; Sinha A; Bauman W
    Clin Physiol; 2001 Jan; 21(1):60-6. PubMed ID: 11168298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombospondin-1 promotes hemostasis through modulation of cAMP signaling in blood platelets.
    Aburima A; Berger M; Spurgeon BEJ; Webb BA; Wraith KS; Febbraio M; Poole AW; Naseem KM
    Blood; 2021 Feb; 137(5):678-689. PubMed ID: 33538796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iloprost binding and inhibition of aggregation in platelet rich plasma. Differences between normal and type IIa hypercholesterolemic subjects.
    Oliva DW; Maderna P; Accomazzo MR; Nicosia S; Tremoli E
    Biochem Pharmacol; 1989 Jan; 38(1):39-45. PubMed ID: 2462881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunophilins are involved in the altered platelet aggregation observed in patients with type 2 diabetes mellitus.
    López E; Berna-Erro A; Hernández-Cruz JM; Salido GM; Redondo PC; Rosado JA
    Curr Med Chem; 2013; 20(14):1912-21. PubMed ID: 23432586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stabilization of standard platelet concentrates and minimization of the platelet storage lesion by a prostacyclin analogue.
    Elias M; Heethuis A; Weggemans M; Bom V; Blom N; McShine RL; Halie MR; Smit Sibinga CT
    Ann Hematol; 1992 Jun; 64(6):292-8. PubMed ID: 1379080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of equimolar concentrations of iloprost, prostacyclin, and prostaglandin E1 on human platelet function.
    Fisher CA; Kappa JR; Sinha AK; Cottrell ED; Reiser HJ; Addonizio VP
    J Lab Clin Med; 1987 Feb; 109(2):184-90. PubMed ID: 2433373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
    Fisch A; Michael-Hepp J; Meyer J; Darius H
    Eur J Pharmacol; 1995 May; 289(3):455-61. PubMed ID: 7556414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human prostacyclin platelet receptors in diabetes mellitus.
    Modesti PA; Fortini A; Gensini GF; Vanni D; Prisco D; Abbate R
    Thromb Res; 1991 Sep; 63(5):541-8. PubMed ID: 1755006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: possible role in platelet hyperactivation in obesity.
    Anfossi G; Russo I; Massucco P; Mattiello L; Doronzo G; De Salve A; Trovati M
    Eur J Clin Invest; 2004 Jul; 34(7):482-9. PubMed ID: 15255785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic.
    Meanwell NA; Rosenfeld MJ; Wright JJ; Brassard CL; Buchanan JO; Federici ME; Fleming JS; Seiler SM
    J Med Chem; 1992 Jan; 35(2):389-97. PubMed ID: 1370696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of vasodilatory prostaglandins with respect to cAMP-mediated phosphorylation of a target substrate in intact human platelets.
    Nolte C; Eigenthaler M; Schanzenbächer P; Walter U
    Biochem Pharmacol; 1991 Jul; 42(2):253-62. PubMed ID: 1713458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The putative prostacyclin receptor antagonist (FCE-22176) is a full agonist on human platelets and NCB-20 cells.
    Wilkins AJ; MacDermot J
    Eur J Pharmacol; 1986 Aug; 127(1-2):117-9. PubMed ID: 2428638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterologous desensitization of platelet adenosine (A2) responses by iloprost.
    MacDermot J; Wilkins AJ; Edwards RJ
    Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():479-81. PubMed ID: 2444081
    [No Abstract]   [Full Text] [Related]  

  • 36. The Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients with Coronary Artery Disease Treated with Aspirin.
    Neergaard-Petersen S; Hvas AM; Grove EL; Larsen SB; Gregersen S; Kristensen SD
    PLoS One; 2015; 10(7):e0132629. PubMed ID: 26148094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential alterations of spontaneous and stimulated 45Ca(2+) uptake by platelets from patients with type I and type II diabetes mellitus.
    Gill JK; Fonseca V; Dandona P; Mikhailidis DP; Angelini GD; Jeremy JY
    J Diabetes Complications; 1999; 13(5-6):271-6. PubMed ID: 10765001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human prostacyclin receptor: cloning and co-expression with EP3 prostaglandin receptor.
    Ortiz-Vega S; Ashby B
    Adv Exp Med Biol; 1997; 433():235-8. PubMed ID: 9561143
    [No Abstract]   [Full Text] [Related]  

  • 39. Enhanced Platelet Sensitivity to IGF-1 in Patients with Type 2 Diabetes Mellitus.
    Gligorijevic N; Robajac D; Nedic O
    Biochemistry (Mosc); 2019 Oct; 84(10):1213-1219. PubMed ID: 31694517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute reversible reduction of PGI2 platelet receptors after iloprost infusion in man.
    Modesti PA; Fortini A; Poggesi L; Boddi M; Abbate R; Gensini GF
    Thromb Res; 1987 Dec; 48(6):663-9. PubMed ID: 2448896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.